WCAMG
ABMD

Woodard & Company Asset Management Group’s Abiomed Inc ABMD Stock Holding History

Woodard & Company Asset Management Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-110
Closed -$49K – 249
2018
Q3 		$49K Hold
110
– – 0.04% 92
2018
Q2 		$45K Buy
110
+20
+22% +$7.25K 0.04% 92
2018
Q1 		$26K Buy
+90
New +$22.8K 0.03% 112

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Woodard & Company Asset Management Group's ABMD Position: Q4 2018 in Review

Woodard & Company Asset Management Group sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 110 shares — an estimated $49K sold.

Woodard & Company Asset Management Group first reported a position in ABMD in Q1 2018 and held it in 3 quarters. The position peaked at $49K in Q3 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

  • Woodard & Company Asset Management Group reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 110 Abiomed Inc shares in Q4 2018, an estimated $49K.
  • Woodard & Company Asset Management Group first reported a position in Abiomed Inc in Q1 2018 and held it in 3 quarters.
  • Woodard & Company Asset Management Group's Abiomed Inc position peaked at $49K in Q3 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Woodard & Company Asset Management Group's 13F filing for Q4 2018, filed 1 Feb 2019.